isupartob sodium (M6229) / Matisse Pharmaceuticals - LARVOL DELTA

Prevalence and treatment of platelet activating histone/anti-histone immune complexes in sepsis (ISTH 2026) - "Aims The prevalence of His-IC in sepsis was investigated and the therapeutic potential of unfractionated heparin and isupartob sodium (Isu), a low-anticoagulant heparinoid, was evaluated...As heparin dose levels are limited by the anticoagulant effect, Isu can be dosed 10-20 times higher thereby suggesting a possible treatment option in sepsis associated . DOI*10.1016/j.rpth.2026.105155"

Cardiovascular • Hematological Disorders • Infectious Disease • Septic Shock • Thrombocytopenia • Thrombosis • ANXA5 • SELP

Matisse Pharmaceuticals receives FDA Fast Track Designation for isupartob sodium in sepsis (GlobeNewswire)

Fast track • Immunology • Inflammation